Submitted by Jorge Silva (jorgelmsilva@ufrrj.br) on 2019-11-12T17:30:03Z No. of bitstreams: 1 2014 - Viviane Horta Gomes.pdf: 701989 bytes, checksum: 69a345d7d48bf6e68e4a639fcdc2258c (MD5) Made available in DSpace on 2019-11-12T17:30:03Z (GMT). No. of bitstreams: 1 2014 - Viviane Horta Gomes.pdf: 701989 bytes, checksum: 69a345d7d48bf6e68e4a639fcdc2258c (MD5) Previous issue date: 2014-08-26 CAPES The aim of this study is to evaluate the sedative effect and the changes caused by nalbuphine in cardiorespiratory parameters, when used alone or in combination with acepromazine in dogs, comparing it with butorphanol. The samples consisted of 8 beagle dogs 3 to 4 years old, healthy, which received four treatments: NALB group (nalbuphine 0.5 mg.kg-1), BUT group (butorphanol 0.15 mg.kg-1), ACPNALB Group (nalbuphine 0.5 mg.kg-1 associated with acepromazine 0.05 mg.kg-1) and ACPBUT group (butorphanol 0.15 mg.kg-1 associated with acepromazine 0.05 mg.kg-1). The opioids were administered twenty minutes following the administration of acepromazine or 0.9% NaCl. Registered: rectal temperature (TEMP), heart rate (HR) and respiratory rate (RR), systolic (SBP), diastolic (DBP) and mean blood pressure (MAP), and degree of sedation (END and ENS), in following time points: Baseline (before administration of acepromazine or 0.9% NaCl), ACP (15' after administration of acepromazine or 0.9% NaCl) and every 15' up to two hours after administration of opioids. The results of this study confirm that the cardiovascular and respiratory systems are little affected when nalbuphine is used at therapeutic doses, and indicate that it promotes mild sedation (NDS = 1 when used alone, for an average of 60 minutes, and moderate sedation (NDS = 2) when associated with acepromazine, for an average of 45 minutes. No relevant differences from the cardiorespiratory point of view were observed when compared with butorphanol, unlike temperature, which was lower when using this drug. Regarding the degree of sedation butorphanol was superior to nalbuphine when isolated (p < 0.05); however, when associated with acepromazine, the sedative scores are similar (NDS = 1), differing in duration of sedative effects, which was higher with butorphanol. It was concluded that nalbuphine can be used as a sedative in dogs, alone or in combination with acepromazine, with confidence about the cardiorespiratory effects, but with fewer sedative effects than butorphanol when applied in isolation. O objetivo desse estudo ? avaliar o efeito sedativo e as altera??es causadas pela nalbufina nos par?metros cardiorrespirat?rios, quando utilizada de forma isolada ou associada ? acepromazina em c?es, comparando-a com o butorfanol. Foram utilizados 8 c?es beagle de 3 a 4 anos de idade, h?gidos, que receberam quatro tratamentos: Grupo NALB (nalbufina 0,5 mg.kg-1), Grupo BUT (butorfanol 0,15 mg.kg-1), Grupo ACPNALB (nalbufina 0,5 mg.kg-1 associada a acepromazina 0,05 mg.kg-1) e Grupo ACPBUT (butorfanol 0,15 mg.kg-1 associado a acepromazina 0,05 mg.kg-1). Os opioides foram administrados vinte minutos ap?s a administra??o da acepromazina ou de NaCl 0,9%. Registrou-se: temperatura retal (TEMP), frequ?ncias card?aca (FC) e respirat?ria (FR), press?o arterial sist?lica (PAS), diast?lica (PAD), e m?dia (PAM), e grau de seda??o (END e ENS), nos seguintes momentos: Basal (anterior ? administra??o da acepromazina ou de NaCl 0,9%), ACP (15?ap?s a administra??o da acepromazina ou de NaCl 0,9%) e a cada 15? at? duas horas ap?s a administra??o do opioide. Os resultados desse estudo confirmam que os aparelhos cardiovascular e respirat?rio s?o pouco afetados quando utiliza-se a nalbufina em doses terap?uticas, e indicam que a mesma promove seda??o leve (END = 1) quando utilizada de forma isolada, por um per?odo m?dio de 60 minutos, e seda??o moderada (END = 2) quando associada ? acepromazina, por um per?odo m?dio de 45 minutos. N?o foram evidenciadas diferen?as relevantes do ponto de vista cardiorrespirat?rio em rela??o ao butorfanol, diferentemente da temperatura, que foi menor quando do uso do mesmo. Em rela??o ao grau de seda??o o butorfanol mostrou-se superior ? nalbufina quando isolados (p < 0.05); por?m, ao serem associados ? acepromazina, os escores sedativos s?o similares (END = 2), diferindo quanto ? dura??o da seda??o, maior na associa??o ao butorfanol. Conclui-se que a nalbufina pode ser utilizada como sedativo em c?es, isoladamente ou associada ? acepromazina, com seguran?a quanto aos efeitos cardiorrespirat?rios, apresentando efeitos sedativos inferiores ao butorfanol quando aplicados de forma isolada.